PhRMA Promotes Cluster Concept In Japan Reform Wish List
Holistic Changes Needed, US Group Says
Executive Summary
US industry association promotes an exchanges with Japan on bioclusters, while continuing to push for holistic debate on reforms to the country’s national healthcare system and changes to reimbursement pricing it sees as supporting innovation.
You may also be interested in...
Japan Readies One-Off Price Cuts For Big Sellers
Japanese regulatory authorities have announced a set of additional reimbursement price cuts for selected products in August, under which Novartis’s heart failure drug Entresto will see its price slashed by 15%. A batch of other newly approved drugs has also been priced.
Japan 2022 Review/Outlook: Supply Crisis, Incentives, Cost Controls In Focus
As Japan's pharma market continues to face supply chain challenges and rising healthcare costs, regulatory authorities are looking to policies that balance incentives in critical areas and temporary price rises with other other ongoing measures to contain the national drugs bill. The Pink Sheet takes a look at the key changes last year and what to expect in 2023.
APAC As A Clinical Trials Powerhouse
In the last 10 years, the Asia Pacific region has become a hotspot for clinical trials, contributing almost 50% of new clinical trial activity globally in 2021, a new infographic analysis by Citeline's Trialtrove shows.